Reassessing Radioactive Iodine Use After Thyroidectomy in Low‐Risk Differentiated Thyroid Cancer: A Systematic Review and Meta‐Analysis
Endocrinology, Diabetes & Metabolism · 2026-09 · 9 (5)
DOI: 10.1002/edm2.70293 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Endocrinology, Diabetes & Metabolism, online erschienen am 28.07.2026. Verfasst von Maheen Asif und 5 weiteren Autor:innen. Beteiligte Einrichtung: Services Institute of Medical Sciences, Lahore, Pakistan. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Iodine Radioisotopes, Thyroidectomy. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Radioactive iodine (RAI) therapy is often administered post‐total thyroidectomy in patients with low‐risk differentiated thyroid carcinoma, despite guidelines advising against its routine application. Evidence regarding the efficacy of RAI in reducing recurrence and improving survival in low‐risk differentiated thyroid cancer (DTC) remains inconsistent.
Methods
We conducted a systematic review and meta‐analysis of observational studies and randomized clinical trials that compare RAI versus no RAI in low‐risk DTC patients. Databases such as MEDLINE, Scopus, Cochrane Library, and Google Scholar were searched through December 2025. Outcomes included recurrence, recurrence‐free survival, treatment response, biochemical markers, and side effects. We performed statistical analysis using Review Manager (RevMan) 5.4 with a random‐effects model, reporting odds ratios (OR) with 95% confidence intervals, and significance set at p < 0.05. Heterogeneity was assessed using I 2 statistics.
Results
Ten studies ( n = 5260) were included in the analysis. No statistically significant difference was observed between the two groups for recurrence (OR 0.66, 95% CI: 0.41–1.08; p = 0.10), 5‐year recurrence‐free survival (OR 2.47, 95% CI: 0.63–9.62; p = 0.19), or treatment response (excellent response: OR 1.00, 95% CI: 0.52–1.92; p = 1.00). Secondary outcomes, including serum thyroglobulin > 1 ng/mL (OR 1.20, 95% CI: 0.00–342.55; p = 0.95), elevated thyroglobulin antibodies (OR 0.91, 95% CI: 0.38–2.16; p = 0.83), xerostomia (OR 5.63, 95% CI: 0.05–667.24; p = 0.48), and dysphonia (OR 0.96, 95% CI: 0.53–1.72; p = 0.88), were also not significantly different between groups, although estimates were not precise.
Conclusion
The available randomized and observational evidence does not demonstrate a clear, clinically meaningful benefit of routine RAI ablation in patients classified as low‐risk DTC. These findings should be interpreted with caution due to heterogeneity across studies, variability in outcome definitions, and the predominance of observational data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Services Institute of Medical Sciences, Lahore, Pakistan.
- King Edward Medical University, Lahore, Pakistan.
- Alzaiem Alazhari University, Khartoum, Sudan.
ORCID-Profile: Maheen Asif, Mudasar Nisar, Aliza Asif, Makzooma Batool, Rabia Javed Iqbal
Zitieren
APA
Asif, M., Nisar, M., Asif, A., Batool, M., Iqbal, R. J., & Amin, M. H. J. (2026). Reassessing Radioactive Iodine Use After Thyroidectomy in Low‐Risk Differentiated Thyroid Cancer: A Systematic Review and Meta‐Analysis. Endocrinology, Diabetes & Metabolism, 9(5). https://doi.org/10.1002/edm2.70293
Vancouver
Asif M, Nisar M, Asif A, Batool M, Iqbal RJ, Amin MHJ. Reassessing Radioactive Iodine Use After Thyroidectomy in Low‐Risk Differentiated Thyroid Cancer: A Systematic Review and Meta‐Analysis. Endocrinology, Diabetes & Metabolism. 2026;9(5). doi:10.1002/edm2.70293
BibTeX
@article{Asif2026,
author = {Asif, Maheen and Nisar, Mudasar and Asif, Aliza and Batool, Makzooma and Iqbal, Rabia Javed and Amin, Mohammed Hammad Jaber},
title = {Reassessing Radioactive Iodine Use After Thyroidectomy in Low‐Risk Differentiated Thyroid Cancer: A Systematic Review and Meta‐Analysis},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2026},
volume = {9},
number = {5},
doi = {10.1002/edm2.70293}
}
EUVIMED